 |
MR Vol.12 No.3 indexに戻る
 |
MODERN RHEUMATOLOGY
Vol.12 No.3 |
 |
|
|
 |
|
|
Gastrointestinal symptoms associated with enteric-coated
sulfasalazine (Azulfidine EN tablets) |
|
|
| S. Okubo1, K. Nakatani2, K. Nishiya3 |
(1)Department of Rheumatology, Misato Marine
Hospital, 1617-5 Niida, Kochi 781-0112, Japan
(2)Department of Orthopedic Surgery, Misato Marine Hospital, Kochi, Japan
(3)Nishiya Internal Clinic, Hiroshima, Japan |
| |
| Abstract |
| Abstract To investigate both the incidence and
the dosage used to treat gastrointestinal (GI) symptoms associated
with enteric-coated sulfasalazine (Azulfidine EN, AZL) in patients
with rheumatoid arthritis (RA), we studied the clinical history of
153 RA patients, and any available data on GI symptoms that might
have been associated with AZL. GI symptoms appeared in 64 (42.5%)
of the 153 cases. There were 19 events of nausea, vomiting, or dyspepsia,
14 events each of epigastric discomfort and reduction or loss of
appetite, 10 events of epigastric, stomach, or abdominal pain, 9
events of heartburn, 8 events of mouth ulcer, 3 events each of loss
of taste and abdominal bloating or borborygmus, 2 events each of
diarrhea or loose stools, hematemesis or melanemia, and gastric or
esophageal ulcer, and 1 event of stomatitis. These results indicate
that GI symptoms associated with AZL are usually mild and treatment
can continue, with almost all cases responding to a reduction in
dose or drug cessation. In some cases, a histamine receptor-2 blocker
or proton pump inhibitor is also required. |
| |
| Key words |
| Key words Adverse drug reactions (ADRs) ・
Azulfidine EN (AZL) ・ Disease-modifying antirheumatic drugs (DMARDs)
・ Gastrointestinal
(GI) symptoms ・ Rheumatoid arthritis (RA) ・ Sulfasalazine (SSZ) |
|
|
 |
|
|
